Show simple item record

dc.contributor.authorWalker, A
dc.contributor.authorKaraszi, K
dc.contributor.authorValentine, Helen R
dc.contributor.authorStrauss, V
dc.contributor.authorChoudhury, Ananya
dc.contributor.authorMcGill, S
dc.contributor.authorWen, K
dc.contributor.authorBrown, Michael D
dc.contributor.authorRamani, Vijay A C
dc.contributor.authorBhattarai, S
dc.contributor.authorTeo, M
dc.contributor.authorYang, L
dc.contributor.authorMyers, K
dc.contributor.authorDeshmukh, N
dc.contributor.authorDenley, H
dc.contributor.authorBrowning, L
dc.contributor.authorLove, S
dc.contributor.authorIyer, G
dc.contributor.authorClarke, Noel W
dc.contributor.authorHall, E
dc.contributor.authorHuddart, R
dc.contributor.authorJames, N
dc.contributor.authorHoskin, Peter J
dc.contributor.authorWest, Catharine ML
dc.contributor.authorKiltie, A
dc.date.accessioned2019-04-29T09:48:55Z
dc.date.available2019-04-29T09:48:55Z
dc.date.issued2019en
dc.identifier.citationWalker AK, Karaszi K, Valentine H, Strauss VY, Choudhury A, McGill S, et al. MRE11 as a predictive biomarker of outcome following radiotherapy in bladder cancer. Int J Radiat Oncol Biol Phys. 2019.en
dc.identifier.pmid30885775en
dc.identifier.doi10.1016/j.ijrobp.2019.03.015en
dc.identifier.urihttp://hdl.handle.net/10541/621752
dc.description.abstractPURPOSE: Organ-confined muscle-invasive bladder cancer (MIBC) is treated with cystectomy or bladder preservation techniques, including radiotherapy. There are currently no biomarkers to inform management decisions and aid patient choice. Previously we showed high levels of MRE11 protein, assessed by immunohistochemistry (IHC), predicted outcome following radiotherapy but not cystectomy. Therefore, we sought to develop the MRE11 IHC assay for clinical use and define its relationship to clinical outcome in samples from two major clinical trials. METHODS AND MATERIALS: Samples from the BCON and BC2001 randomised controlled trials and a cystectomy cohort were stained using automated IHC methods and scored for MRE11 in three UK centres. RESULTS: Despite step-wise creation of scoring cards and standard operating procedures for staining and interpretation, there was poor inter-centre scoring agreement (Kappa 0.32, 95% CI 0.17-0.47). There were no significant associations between MRE11 scores and cause-specific survival (CSS) identified in BCON (n=132) and BC2001 (n=221) samples. Re-optimised staining improved agreement between scores from BCON tissue microarrays (n=116), but MRE11 expression was not prognostic for CSS. CONCLUSIONS: Manual IHC scoring of MRE11 was not validated as a reproducible biomarker of radiation-based bladder preservation success. There is a need for automated quantitative methods and/or a reassessment of how DNA-damage response relates to clinical outcomes.en
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1016/j.ijrobp.2019.03.015en
dc.titleMRE11 as a predictive biomarker of outcome following radiotherapy in bladder canceren
dc.typeArticleen
dc.contributor.departmentCRUK/MRC Oxford Institute for Radiation Oncology, University of Oxford, Oxford OX3 7DQ, UKen
dc.identifier.journalInternational Journal of Radiation Oncology, Biology, Physicsen
dc.description.noteen]


Files in this item

This item appears in the following Collection(s)

Show simple item record